Taheri Mohsen, Motalebzadeh Jamshid, Mahjoubi Frouzandeh
Department of Clinical Genetics, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Department of Genetics, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Email:
Asian Pac J Cancer Prev. 2018 Nov 29;19(11):3111-3115. doi: 10.31557/APJCP.2018.19.11.3111.
Background: Breast cancer is the most common malignancy in women. Multidrug resistance (MDR) is still a great obstacle of breast cancer chemotherapy. We have previously shown that multidrug resistance-associated protein 1 (MRP1) is associated with response to neoadjuvant chemotherapy. The lung resistance-related protein (LRP) is identified as a prognostic marker and response to treatment factor which has been studied mainly in hematological malignancy and leukemia. In this study, we aimed to analyze LRP expression and possible correlation between the expression level of this gene with MRP1 as a candidate marker for chemotherapy resistance. Materials and Methods: We collected 54 breast tumors and adjacent normal tissues from Iranian breast cancer patients and Real time RT-PCR was employed to measure the gene expression level in our samples. Results: MRP1 and LRP expression level were significantly lower in tumor tissues of the patients responding to chemotherapy compared to non-responding patients. No relation between the expression level of either of these genes and clinicopathology markers was found. Conclusion: Our results suggest that LRP gene expression is correlated to MRP1 in human breast cancer cells and may affect the clinical response to treatment.
乳腺癌是女性中最常见的恶性肿瘤。多药耐药(MDR)仍然是乳腺癌化疗的一大障碍。我们之前已经表明多药耐药相关蛋白1(MRP1)与新辅助化疗的反应有关。肺耐药相关蛋白(LRP)被确定为一种预后标志物和治疗反应因子,其主要在血液系统恶性肿瘤和白血病中得到研究。在本研究中,我们旨在分析LRP的表达以及该基因表达水平与作为化疗耐药候选标志物的MRP1之间可能存在的相关性。
我们从伊朗乳腺癌患者中收集了54个乳腺肿瘤及相邻正常组织,并采用实时RT-PCR来测量我们样本中的基因表达水平。
与无反应患者相比,化疗有反应患者的肿瘤组织中MRP1和LRP表达水平显著更低。未发现这两个基因中任何一个的表达水平与临床病理标志物之间存在关联。
我们的结果表明LRP基因表达在人乳腺癌细胞中与MRP1相关,并且可能影响临床治疗反应。